-- Scott Roberts
MONDAY, June 24 (HealthDay News) -- The antibiotic Vibativ
(telavancin) has been approved by the U.S. Food and Drug
Administration to treat pneumonia caused by
Staphylococcus aureusbacteria when other treatments aren't
Pneumonia, a lung infection, can be caused by different bacteria
S. aureusinfection often affects people in hospitals,
notably those on ventilators. Such infections can be serious, since
people on a ventilator often have a weakened immune system and are
unable to fight an infection, the FDA said in a news release.
Vibativ's safety and effectiveness were evaluated clinically
among 1,532 people. The studies found the drug was about as
effective in treating
S. aureuspneumonia as another approved antibiotic,
However, the studies found that more people treated with Vibativ
died if they also had kidney problems, compared to kidney patients
who took vancomycin. The FDA said it would add this information to
Vibativ's label. The most common clinical side effect of Vibativ is
Vibativ was first approved in 2009 to treat skin infections. The
drug is marketed by San Francisco-based Theravance Inc.
The FDA has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.